Congenital dyserythropoietic anemia, type 1, in a polynesian patient: Response to interferon α2b

Laurent Roda, Jérôme Pasche, Alain Fournier, Vaea Terorotua, Sunitha N. Wickramasinghe, Hannah Tamary, Pierre Olivier Schischmanoff, Gil Tchernia, Jean Delaunay*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The authors attempted to assess the utility of interferon α2b treatment in a Polynesian girl with a relatively severe form of congenital dyserythropoietic anemia, type 1. The diagnosis was established using routine hematologic and biochemical tests, light and electron microscopy, and electrophoresis of red cell membrane proteins. Response to the treatment was monitored using the blood count and reticulocyte count. The patient was age 14 when interferon treatment was started. Previously, she had been partially dependent on transfusions, and gallstones and iron overload had developed. The dose of interferon α2b was initially 3 × 106 units three times a week for 1 year and 3 × 106 units twice a week thereafter. On this treatment, hemoglobin and reticulocytes increased and transfusions became unnecessary. In keeping with a few previous reports, interferon α2b proved to be effective in congenital dyserythropoietic anemia, type 1. The patient became transfusion-independent. More cases need to be studied to optimize the dosage of interferon α2b and determine how long the treatment can be tolerated.

Original languageEnglish
Pages (from-to)503-506
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Issue number6
StatePublished - Aug 2002
Externally publishedYes


  • Congenital dyserythropoietic anemia, type 1
  • Hemoglobin level
  • Interferon α2b
  • Polynesia


Dive into the research topics of 'Congenital dyserythropoietic anemia, type 1, in a polynesian patient: Response to interferon α2b'. Together they form a unique fingerprint.

Cite this